Literature DB >> 17923476

CaMKIIdelta isoforms differentially affect calcium handling but similarly regulate HDAC/MEF2 transcriptional responses.

Tong Zhang1, Michael Kohlhaas, Johannes Backs, Shikha Mishra, William Phillips, Nataliya Dybkova, Shurong Chang, Haiyun Ling, Donald M Bers, Lars S Maier, Eric N Olson, Joan Heller Brown.   

Abstract

The delta(B) and delta(C) splice variants of Ca(2+)/calmodulin-dependent protein kinase II (CaMKII), which differ by the presence of a nuclear localization sequence, are both expressed in cardiomyocytes. We used transgenic (TG) mice and CaMKII expression in cardiomyocytes to test the hypothesis that the CaMKIIdelta(C) isoform regulates cytosolic Ca(2+) handling and the delta(B) isoform, which localizes to the nucleus, regulates gene transcription. Phosphorylation of CaMKII sites on the ryanodine receptor (RyR) and on phospholamban (PLB) were increased in CaMKIIdelta(C) TG. This was associated with markedly enhanced sarcoplasmic reticulum (SR) Ca(2+) spark frequency and decreased SR Ca(2+) content in cardiomyocytes. None of these parameters were altered in TG mice expressing the nuclear-targeted CaMKIIdelta(B). In contrast, cardiac expression of either CaMKIIdelta(B) or delta(C) induced transactivation of myocyte enhancer factor 2 (MEF2) gene expression and up-regulated hypertrophic marker genes. Studies using rat ventricular cardiomyocytes confirmed that CaMKIIdelta(B) and delta(C) both regulate MEF2-luciferase gene expression, increase histone deacetylase 4 (HDAC4) association with 14-3-3, and induce HDAC4 translocation from nucleus to cytoplasm, indicating that either isoform can stimulate HDAC4 phosphorylation. Finally, HDAC4 kinase activity was shown to be increased in cardiac homogenates from either CaMKIIdelta(B) or delta(C) TG mice. Thus CaMKIIdelta isoforms have similar effects on hypertrophic gene expression but disparate effects on Ca(2+) handling, suggesting distinct roles for CaMKIIdelta isoform activation in the pathogenesis of cardiac hypertrophy versus heart failure.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17923476     DOI: 10.1074/jbc.M707083200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  101 in total

1.  Heterogeneous myocyte enhancer factor-2 (Mef2) activation in myocytes predicts focal scarring in hypertrophic cardiomyopathy.

Authors:  Tetsuo Konno; Dan Chen; Libin Wang; Hiroko Wakimoto; Polakit Teekakirikul; Matthew Nayor; Masataka Kawana; Seda Eminaga; Joshua M Gorham; Kumar Pandya; Oliver Smithies; Francisco J Naya; Eric N Olson; J G Seidman; Christine E Seidman
Journal:  Proc Natl Acad Sci U S A       Date:  2010-10-05       Impact factor: 11.205

Review 2.  Cardiac hypertrophy and heart failure development through Gq and CaM kinase II signaling.

Authors:  Shikha Mishra; Haiyun Ling; Michael Grimm; Tong Zhang; Don M Bers; Joan Heller Brown
Journal:  J Cardiovasc Pharmacol       Date:  2010-12       Impact factor: 3.105

Review 3.  CaMKII in myocardial hypertrophy and heart failure.

Authors:  Mark E Anderson; Joan Heller Brown; Donald M Bers
Journal:  J Mol Cell Cardiol       Date:  2011-01-27       Impact factor: 5.000

4.  Ca2+/calmodulin-dependent protein kinase II-γ (CaMKIIγ) negatively regulates vascular smooth muscle cell proliferation and vascular remodeling.

Authors:  Fatima Z Saddouk; Li-Yan Sun; Yong Feng Liu; Miao Jiang; Diane V Singer; Johannes Backs; Dee Van Riper; Roman Ginnan; John J Schwarz; Harold A Singer
Journal:  FASEB J       Date:  2015-11-13       Impact factor: 5.191

5.  Dysfunctional ryanodine receptor and cardiac hypertrophy: role of signaling molecules.

Authors:  Naohiro Yamaguchi; Asima Chakraborty; Daniel A Pasek; Jeffery D Molkentin; Gerhard Meissner
Journal:  Am J Physiol Heart Circ Physiol       Date:  2011-03-18       Impact factor: 4.733

6.  Genome-wide analysis of histone marks identifying an epigenetic signature of promoters and enhancers underlying cardiac hypertrophy.

Authors:  Roberto Papait; Paola Cattaneo; Paolo Kunderfranco; Carolina Greco; Pierluigi Carullo; Alessandro Guffanti; Valentina Viganò; Giuliano Giuseppe Stirparo; Michael V G Latronico; Gerd Hasenfuss; Ju Chen; Gianluigi Condorelli
Journal:  Proc Natl Acad Sci U S A       Date:  2013-11-27       Impact factor: 11.205

Review 7.  Eicosanoid signalling pathways in the heart.

Authors:  Christopher M Jenkins; Ari Cedars; Richard W Gross
Journal:  Cardiovasc Res       Date:  2008-12-14       Impact factor: 10.787

Review 8.  New therapeutic targets in cardiology: arrhythmias and Ca2+/calmodulin-dependent kinase II (CaMKII).

Authors:  Adam G Rokita; Mark E Anderson
Journal:  Circulation       Date:  2012-10-23       Impact factor: 29.690

Review 9.  The role of O-GlcNAc transferase in regulating the gene transcription of developing and failing hearts.

Authors:  Heidi M Medford; Susan A Marsh
Journal:  Future Cardiol       Date:  2014-11

10.  Ranolazine prevents pressure overload-induced cardiac hypertrophy and heart failure by restoring aberrant Na+ and Ca2+ handling.

Authors:  Jiali Nie; Quanlu Duan; Mengying He; Xianqing Li; Bei Wang; Chi Zhou; Lujin Wu; Zheng Wen; Chen Chen; Dao Wu Wang; Katherina M Alsina; Xander H T Wehrens; Dao Wen Wang; Li Ni
Journal:  J Cell Physiol       Date:  2018-11-29       Impact factor: 6.384

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.